

Centre for AIDS Reagents.



Page 1 of 2

Data Sheet

NAME:	SC422661, clone 8 (SVPB8)
REPOSITORY REFERENCE: NOTE: This clone is also availa	ARP2065 ble as a member of a panel set, see ARP2066
NOTE. This clone is also availa	ble as a member of a paner set, see ARI 2000
PROVIDED:	20 μg plasmid DNA/per vial (0.5 mg/ml)
CLONING SITE:	The HIV-1 env/rev cassette was T/A cloned into the cloning site of pcDNA3.1/V5-His TOPO© expression vector, in the correct orientation with the CMV promoter. The size of the insert is 2886 bp.
CLONING VECTOR:	pcDNA3.1/V5-His TOPO©. The size of the cloning vector including the insert is 8409 bp.
DESCRIPTION:	A PCR fragment containing full-length env and rev genes was derived from plasma virion-associated RNA from a subject acutely infected with a clade B virus by reverse transcription and nested PCR amplification procedures. The env/rev cassette was cloned into pcDNA3.1/V5-His TOPO© expression vector by a T/A cloning approach. A single transformed ampicillin-resistant <i>E. coli</i> colony was selected and expanded.
SPECIAL CHARACTERISTICS:	The clone represents env/rev sequences from a subject with early subtype B infection (female to male transmission in Trinidad). The clone expresses a functional env/rev cassette and can be used to generate pseudotyped infectious virions that use CCR5 as the viral coreceptor. SC422661.8 Env containing pseudovirions are included in a standard virus neutralization panel for subtype B strains (SVPB8).

Version 1

PLASMID EXPANSION:

It is recommended that this plasmid be expanded using

TOP 10 Competent Cells in LB medium at 30°C.

GENE BANK:

Accession number is AY835441

STORAGE:

-80°C

SOURCE:

Drs. D. Montefiori, Dr. Feng Gao and Dr. Ming Li. (Courtesy of NIH AIDS Research and Reference Reagent

Programme.)

REFERENCE:

Li, M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. *J. Virology* **79**(16):

10108-10125, 2005.

ACKNOWLEDGEMENTS:

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html in the "Acknowledgements" section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)

Version 1 Page 2 of 2